Clinical Trial Update: The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the combination of anlotinib with immune checkpoint inhibitors in advanced non-small cell lung cancer patients who have undergone mul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: The Affiliated Hospital of Qingdao University | Conditions: NSCLC, Angiogenesis | Phase 1, Phase 2 | Status: COMPLETED